<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04414735</url>
  </required_header>
  <id_info>
    <org_study_id>HCB/2018/0853</org_study_id>
    <nct_id>NCT04414735</nct_id>
  </id_info>
  <brief_title>Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Recipients</brief_title>
  <official_title>Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to evaluate the superiority of photopheresis in combination
      with the standard immunosuppression vs standard immunosuppression alone for the prevention of
      acute rejection in highly sensitized kidney transplant recipients (cPRA ≥90%).

      Unicentric, randomized, open study.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Unicentric, randomized, open study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first histological rejection in the first year of kidney transplantation.</measure>
    <time_frame>1 year after kidney transplantation</time_frame>
    <description>Time to first histological rejection in the first year of kidney transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biopsy proved acute rejection</measure>
    <time_frame>1 year after kidney transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtrate rate at one year after kidney transplant</measure>
    <time_frame>1 year after kidney transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Kidney Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>1- Control group (Standard immunosuppression)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>1- Control group (n=15): Standard immunosuppression (Thymoglobulin, Prednisone, Tacrolimus, and Everolimus or Mycophenolate), according to the clinical protocol of the Nephrology and Kidney Transplant Department.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2- Treatment group (ECP+Standard immunosuppression)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2- Treatment group (n=15): Extracorporeal photopheresis in combination with standard immunosuppression (Thymoglobulin, Prednisone, Tacrolimus, and Everolimus or Mycophenolate) according to the clinical protocol of the Nephrology and Kidney Transplant Department</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Extracorporeal Photopheresis</intervention_name>
    <description>Infusion of autologous cellular products exposed to ultraviolet light (UV), in the presence of a photosensitizer. The cellular product is obtained through leucopheresis and its subsequent exposure to 8-methoxypsoralen (8-MOP) and irradiation with UV-A light.</description>
    <arm_group_label>2- Treatment group (ECP+Standard immunosuppression)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sensitized (cPRA ≥90%) candidates for a deceased-donor kidney transplantation

          -  Recipients between 18 and 75 years old

          -  Patients are able to understand and sign informed consent (Annex 1).

        Exclusion Criteria:

          -  Participation in another interventional clinical trial.

          -  Use of Rituximab or Eculizumab at the time of transplant or in the first 24 hours
             post-transplant.

          -  Persons with any dependency on the researcher or employee by the responsible
             institution or researcher. As well as people detained by legal order.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Deparment of Nephology and Kidney Transplant</name>
      <address>
        <city>Barcelona</city>
        <state>Please Select</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Gastón J Piñeiro, MD</last_name>
      <email>gjpineir@clinic.cat</email>
    </contact>
    <contact_backup>
      <last_name>Fritz Diekmann, MD, PhD</last_name>
      <email>fdiekman@clinic.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Gastón J Piñeiro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fritz Diekmann, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jordi Rovira, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro Ventura, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Jaksch P, Knobler R. ECP and solid organ transplantation. Transfus Apher Sci. 2014 Jun;50(3):358-62. doi: 10.1016/j.transci.2014.04.006. Epub 2014 Apr 13. Review.</citation>
    <PMID>24768429</PMID>
  </reference>
  <reference>
    <citation>Heshmati F. Updating ECP action mechanisms. Transfus Apher Sci. 2014 Jun;50(3):330-9. doi: 10.1016/j.transci.2014.04.003. Epub 2014 Apr 13. Review.</citation>
    <PMID>24837416</PMID>
  </reference>
  <reference>
    <citation>Rose EA, Barr ML, Xu H, Pepino P, Murphy MP, McGovern MA, Ratner AJ, Watkins JF, Marboe CC, Berger CL. Photochemotherapy in human heart transplant recipients at high risk for fatal rejection. J Heart Lung Transplant. 1992 Jul-Aug;11(4 Pt 1):746-50.</citation>
    <PMID>1498142</PMID>
  </reference>
  <reference>
    <citation>Barr ML, Meiser BM, Eisen HJ, Roberts RF, Livi U, Dall'Amico R, Dorent R, Rogers JG, Radovancević B, Taylor DO, Jeevanandam V, Marboe CC. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med. 1998 Dec 10;339(24):1744-51.</citation>
    <PMID>9845709</PMID>
  </reference>
  <reference>
    <citation>Barr ML, Baker CJ, Schenkel FA, McLaughlin SN, Stouch BC, Starnes VA, Rose EA. Prophylactic photopheresis and chronic rejection: effects on graft intimal hyperplasia in cardiac transplantation. Clin Transplant. 2000 Apr;14(2):162-6.</citation>
    <PMID>10770423</PMID>
  </reference>
  <reference>
    <citation>Kirklin JK, Brown RN, Huang ST, Naftel DC, Hubbard SM, Rayburn BK, McGiffin DC, Bourge RB, Benza RL, Tallaj JA, Pinderski LJ, Pamboukian SV, George JF, Marques M. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. J Heart Lung Transplant. 2006 Mar;25(3):283-8. Epub 2006 Jan 25.</citation>
    <PMID>16507420</PMID>
  </reference>
  <reference>
    <citation>Pecoraro Y, Carillo C, Diso D, Mantovani S, Cimino G, De Giacomo T, Troiani P, Shafii M, Gherzi L, Amore D, Rendina EA, Venuta F, Anile M. Efficacy of Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome After Lung Transplantation. Transplant Proc. 2017 May;49(4):695-698. doi: 10.1016/j.transproceed.2017.02.035.</citation>
    <PMID>28457374</PMID>
  </reference>
  <reference>
    <citation>Jaksch P, Scheed A, Keplinger M, Ernst MB, Dani T, Just U, Nahavandi H, Klepetko W, Knobler R. A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant. 2012 Sep;31(9):950-7. doi: 10.1016/j.healun.2012.05.002.</citation>
    <PMID>22884382</PMID>
  </reference>
  <reference>
    <citation>Kusztal M, Kościelska-Kasprzak K, Gdowska W, Zabińska M, Myszka M, Kłak R, Krajewska M, Boratyńska M, Szyber P, Chudoba P, Patrzałek D, Klinger M. Extracorporeal photopheresis as an antirejection prophylaxis in kidney transplant recipients: preliminary results. Transplant Proc. 2011 Oct;43(8):2938-40. doi: 10.1016/j.transproceed.2011.08.061.</citation>
    <PMID>21996194</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 30, 2020</study_first_submitted>
  <study_first_submitted_qc>May 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Fritz Diekmann</investigator_full_name>
    <investigator_title>Head of the Experimental Laboratory of Nephrology and Transplantation (LENIT)</investigator_title>
  </responsible_party>
  <keyword>Kidney Transplant Rejection</keyword>
  <keyword>photopheresis</keyword>
  <keyword>Antibody-mediated rejection</keyword>
  <keyword>Chronic active antibody-mediated rejection</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

